Can upfront DPYD extended variant testing reduce toxicity and associated hospital costs of fluoropyrimidine chemotherapy? A propensity score matched analysis of 2022 UK patients

AIM: To independently assess the impact of mandatory testing using an extended DPYD variant panel (ToxNav®) and consequent dose adjustment of Capecitabine/5-FU on recorded quantitative toxicity, symptoms of depression, and hospital costs. METHODS: We used propensity score matching (PSM) to match 466...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsiachristas, Apostolos, Vallance, Grant, Koleva-Kolarova, Rositsa, Taylor, Harriet, Solomons, Luke, Rizzo, Giovanni, Chaytor, Catherine, Miah, Junel, Wordsworth, Sarah, Hassan, A. Bassim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044697/
https://www.ncbi.nlm.nih.gov/pubmed/35473510
http://dx.doi.org/10.1186/s12885-022-09576-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044697/
https://www.ncbi.nlm.nih.gov/pubmed/35473510
http://dx.doi.org/10.1186/s12885-022-09576-3

Ejemplares similares